Poster: CT-025 Impact of Stem Cell Source on Outcome of Allogeneic Stem Cell Transplantation in Pediatric Cancer

BM was the most commonly used graft source in 92.5% of cases with OS of 81.9% and EFS of 70.9%. PB was only used in 7.5% with 50% OS and 33.3% EFS (P value =0.021). MRD was used in 86% of patients, while 10.1% received their allograft from haploidentical donors. At the end of the study 64.8% of the patients were alive, 34.6% died while only one patient lost follow up. With median duration of follow up of 64 months, the 3-year overall survival of the whole patients was 64% Conclusions: Bone marrow has a better survival outcome as a source of stem cell in allogeneic SCT than peripheral blood. However, it should be noted than PB SCT was used in Juvenile myelomonocytic leukemia patients which is known to have the worst outcome when transplanted.